Observations on Tumor and Metastatic Suppressor Gene Status in Human Fibrous Neoplasms with Particular Emphasis on p53 and nm23

Abstract

Eighty-two soft-tissue sarcomas, including 50 patients with dermatofibrosarcoma protuberans (DFSP), 16 patients with fibrosarcomas (FS), and 16 patients with malignant fibrous histiocytoma (MFH), were investigated for the presence of p53 mutations and for p53, nm23 immunoreactivity with silver-staining polymerase chain reaction-single-strand conformation polymorphism and immunohistochemistry methods. The total mutation rate of p53 gene was 23% (3 of 50 DFSP, 7 of 16 FS and 9 of 16 MFH). Of 82 tumor samples, 22% (2 of 50 DFSP, 6 of 16 FS, and 10 of 16 MFH) were positive for p53 immunostaining. p53 gene mutation and expression were low in DFSP (6.0%; 4.0%) but high in FS (43.8%; 37.5%) and in MFH (56.3%; 62.5%). NDPK/nm23 expression was high in DFSP (84.0%) but was low in FS (31.3%) and in MFH (18.8%). High levels of p53 gene mutation and expression correlated with metastasis and degree of malignancy. On the contrary, low levels of NDPK/nm23 expression correlated with metastasis and degree of malignancy of human fibrous neoplasms. p53 mutations in soft-tissue sarcomas have a similar spectrum to those in carcinomas. Determination of p53 gene mutation and expression in combination with low nm23/NDPK expression may help predict metastasis and degree of malignancy of fibrous neoplasms. The precise association between the p53 gene and nm23 gene remains to be established.

Keywords

soft-tissue sarcomas p53 gene nm23 gene polymerase chain reaction-single-strand conformation polymorphism

Get full access to this article

View all access options for this article.

References

1. Batsakis JG , El-Naggar AK . p53: Fifteen years after discovery. Adv Anat Pathol 2:71-86, 1995

2. Hollstein M , Sidransky D , Vogelstein B , Harris CC . p53 mutations in human cancers. Science 253:49-53, 1991

3. Jankowski SA , Mitchell DS , Smith SH , Trent JM , Meltzer PS . SAS, a gene amplified in human sarcomas, encodes a new member of the transmembrane 4 superfamily of proteins. Oncogene 9: 1205-1211, 1994

4. Momand J , Zambetti GP , Olson DC , George D , Levine AJ . The mdm-2 oncogene product forms a complex with the p53 protein and p53 mediated transactivation. Cell 69:1237-1245, 1992

5. Andreassen A , Oyjord T , Hovig E , Holm R , Florenes VA , Nesland JM . p53 abnormalities in different subtypes of human sarcomas. Cancer Res 53:468-471, 1993

6. Taubert H , Wurl P , Meye A , Berger D , Thamm B , Neu-mann K , Hinze R , Schmidt H , Rath FW . Molecular and immunohistiocytoma, identification of seven new mutations for soft tissue sarcomas. Cancer 76:1187-1196, 1995

7. Liu FS , Kohler MF , Marks JR , Bast RC , Boyd J , Berchuck A . Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 83:118-124, 1994

8. Cordon-Cardo C , Latres E , Drobnjak M , Oliva MR , Pollack D , Woodruff JM , Cardon-Cardo C . Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcoma. Am J Pathol 145:345-355, 1994

9. Latres E , Drobnjak M , Pollack D , Oliva MR , Ramos M , Karpeh M , Woodruff JM , Cordon-Cardo C . Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcoma. Am J Pathol 145:345-355, 1994

10.

10. Castresana JS , Barrios C , Gomez L , Kreicbergs A . No association between c-myc amplification and TP53 mutation in sarcoma tumorigenesis. Cancer Genet Cytogenet 76:47-49, 1994

11.

11. Toguchida J , Yamaguchi T , Ritchie B , Beauchamp RL , Dayton SH , Herrera GE . Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52:6194-6199, 1992

12.

12. Boman F , Peters J , Ragge N , Triche T . Infrequent mutation of the p53 gene in fibrous tumors of infancy and childhood. Diagn Mol Pathol 2:14-22, 1994

13.

13. Soini Y , Vahakangas K , Nuorva K , Kamel D , Lane DP , Paakko P . p53 immunohistochemistry in malignant fibrous histiocytomas and other mesenchymal tumors. J Pathol 168:29-33, 1992

14.

14. Kawai A , Noguchi M , Beppu Y , Yokoyama R , Mukai K , Hirohashi S . Nuclear immunoreactions of p53 protein in soft tissue sarcomas. Cancer 73:2499-2505, 1994

15.

15. Cariello NF , Beroud C , Soussi T . Database and software for the analysis of mutations at the human p53 gene. Nucl Acids Res 22:3549-3550, 1994

16.

16. Steeg PS , Bevilacqua G , Kopper L , Thorgeirsson UP , Talmadge JE , Liotta LA . Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 200:80-84, 1988

17.

17. Stahl JA , Leone A , Rosengard AM , Porter L , King CR , Steeg PC . Identification of a second human nm23 gene, nm23-H2. Cancer Res 51:445-449, 1991

18.

18. Bevilacqua G , Sobel ME , Liotta LA , Steeg PS . Association of low nm23 RNA levels in human primary infiltrating ductal carcinomas with lymph node involvement and other histological indicators of high metastatic potential. Cancer Res 49:5185-5190, 1989

19.

19. Cohn KH , Wang F , Desoto-LaPaix F , Solomon WB , Patterson LG , Arnold MR . Association of nm23-HI allelic deletions with distant metastases in colorectal carcinoma. Lancet 338:722-724, 1991

20.

20. Nakayama T , Ohtsuru A , Nakao K , Shima M , Nakata K , Watanabe K . Expression in hepatocellular carcinoma of homolog of the nm23 gene product. J Natl Cancer Inst 84:1349-1354, 1992

21.

21. Van Unnik JAM , Coindre J , Contesso G , Albus-Lutter CE , Schiodt T , Garcia-Miralles T . Grading of soft tissue sarcomas: experience of the EORTC. In Ryan JR , Baker LO (eds): Soft Tissue and Bone Sarcoma Treatment. Dordrecht: Kluwer Academic Publishers, pp. 7-13, 1988

22.

22. Wright DK , Manos MM . Sample preparation from paraffin-embedded tissue. In PCR Protocol: A Guide to Method and Applications. Academic Press, San Diego, pp. 153-158, 1990

23.

23. Sammoris DW , Adams LD , Nishizawa EE . Ultrasensitive silver-based color staining of polypeptides in polyacrylamide gels. Electrophoresis 2:135-141, 1981

24.

24. Dei Tos AP , Doglioni C , Laurino L , Barbareschi M , Fletcher CDM . p53 protein expression in non-neoplastic lesions and benign and malignant neoplasm of soft tissue. Histopathology 22:45-50, 1993

25.

25. Wadayama B , Toguchida J , Yamaguchi T , Sasaki MS , Kotoura Y , Yamamuro T . p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br J Cancer 68:1134-1139, 1993

26.

26. Brenner W , Schaefler K , Chhabra H . Dermatofibrosarcoma protuberans metastatic to a regional with lymph node: Report of a case and review. Cancer 36:1897-1902, 1975

27.

27. Noguchi M , Maezawa N , Nakanishi Y . Application of the p53 gene mutation pattern for differential diagnosis of primary versus metastatic lung carcinoma. Diagn Mol Pathol 2:29-35, 1993

28.

28. Hirayama R , Sawai S , Takagi Y , Mishima Y , Kimura N , Shimada N , Esaki Y , Kurashima C , Utsuyama M , Hirokawa R . Positive relationship between expression of antimetastatic factor (nm23 gene product or nucleoside diphosphate kinase) and good prognosis in human breast cancer. J Natl Cancer Inst 83:1249-1250, 1991

29.

29. Hennessy C , Henry JA , May FEB , Westley BR , Angus B , Lennard TWJ . Expression of the antimetastatic gene nm23 in human breast cancer: An association with good prognosis. J Natl Cancer Inst 83:281-285, 1991